Boston Scientific Appoints New COO, Announces New Operating Structure

Boston Scientific (BSX) announced the promotion of Joe Fitzgerald to the newly created role of Executive Vice President and Chief Operating Officer. In conjunction with this leadership change, the company will reorganize its business into three new reportable segments to enhance operational efficiency and support continued growth.

Key Details

• COO Appointment: Joe Fitzgerald, currently EVP and Group President of Cardiovascular, will become COO effective January 1, 2027.
• New Operating Structure: Also effective January 1, 2027, BSX will realign into three global segments: Interventional Therapies, Rhythm Solutions, and MedSurg.
• COO Compensation: Mr. Fitzgerald's new compensation includes an annual base salary of $1,050,000, a bonus target of 110% of base salary, and a 2027 equity award valued at $7,000,000.
• CAO Transition: Mark Bickel has been appointed to succeed Emily Woodworth as Chief Accounting Officer, effective March 1, 2027.